
NASDAQHealthcareMedical - Devices
ข้อมูลล่าสุด
US$2.30
−US$0.42 · -15.44%
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
ณ ราคาปิด
US$2.30
−US$0.42 · -15.44%
หลังปิดตลาด
US$2.29
−US$0.01 · -0.43%
8 ต.ค. 16:15 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
ช่วงราคารายวัน
ปัจจุบัน US$2.30
ช่วง 52 สัปดาห์
ปัจจุบัน US$2.30
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ขาย
มูลค่า
57
มูลค่ายุติธรรม
ความเชื่อมั่น
43
ผสม
ความเสี่ยง
77
ความเสี่ยงสูง
โมเมนตัม
48
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
ช่วงราคารายวัน
ปัจจุบัน US$2.30
ช่วง 52 สัปดาห์
ปัจจุบัน US$2.30
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 160.01M USD | 154.01M USD | 200.52M USD | 128.3M USD | 130.51M USD |
| ต้นทุนสินค้าขาย | 109.33M USD | 116.73M USD | 147.74M USD | 79.27M USD | 71.65M USD |
| กำไรขั้นต้น | 50.67M USD | 37.28M USD | 52.78M USD | 49.04M USD | 58.86M USD |
| การวิจัยและพัฒนา | 97.31M USD | 134.92M USD | 187.17M USD | 193M USD | 112.9M USD |
| การขาย ทั่วไป และธุรการ | 141.49M USD | 175.02M USD | 169.82M USD | 160.85M USD | 124.12M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 608.24M USD | 511.6M USD | 387.25M USD | 356.23M USD | 269.3M USD |
| ดอกเบี้ยจ่าย | 6.95M USD | 13.41M USD | 14.34M USD | 14.69M USD | 12.53M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 386.41M USD | 53.35M USD | 32.69M USD | 17.32M USD | 11.59M USD |
| รายได้จากการดำเนินงาน | −557.56M USD | −474.31M USD | −334.47M USD | −307.2M USD | −210.44M USD |
| รายได้สุทธิ | −546.38M USD | −309.85M USD | −306.74M USD | −314.25M USD | −181.22M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 8 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$1.18
โอกาสปรับลง 48.70%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
ARK Innovation ETFARKK55.82M0.50%5.56B USD0.75%US$87.60-0.79%
ARK Genomic Revolution ETFARKG30.24M1.43%1.56B USD0.75%US$49.29-1.70%
iShares Russell 2000 ETFIWM20.38M0.03%78.56B USD0.19%US$277.63-0.03%
Vanguard Morningstar Total Stock Market ETFVTI12.92M0.00%2.3T USD0.03%US$379.56-0.39%
iShares Russell 2000 Growth ETFIWO6.79M0.05%14.25B USD0.24%US$353.47-0.53%
iShares Biotechnology ETFIBB5.99M0.06%10.4B USD0.44%US$200.48-1.41%
Vanguard Extended Market ETFVXF4.92M0.01%95.4B USD0.05%US$233.13-0.15%
Schwab U.S. Small-Cap ETFSCHA4.41M0.02%21.7B USD0.03%US$32.66+0.15%
ARK Innovation ETFARKK
ARK Genomic Revolution ETFARKG
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Extended Market ETFVXF
Schwab U.S. Small-Cap ETFSCHAเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน